Clasificación en acciones
#10096
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated... Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Precio por acción
$19.81
Última sincronización: 2026-08-28
Capitalización bursátil
$891.32M
Comercio Beta Bionics, Inc. (BBNX)
Ganancias de Beta Bionics, Inc. (BBNX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Beta Bionics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Beta Bionics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
| Año |
Ganancias |
Cambiar |
|
Not enough data for the provided dates. |
Ganancias de empresas similares o competidoras
| Empresa |
Ganancias |
Diferencia de ganancias |
País |
|
|
$7.51B |
-
|
US
|
|
|
$5.15B |
-
|
US
|
|
|
$5.56B |
-
|
IE
|
|
|
$3.86B |
-
|
US
|
|
|
- |
-
|
DE
|